Introduction {#tca12900-sec-0005}
============

Lung cancer, the leading cause of cancer‐related death, is the most commonly diagnosed malignant carcinoma in men and the second most common in women worldwide.[1](#tca12900-bib-0001){ref-type="ref"}, [2](#tca12900-bib-0002){ref-type="ref"} More than one million deaths are attributed to lung cancer each year.[3](#tca12900-bib-0003){ref-type="ref"} However, the exact cause and molecular mechanisms of lung cancer are not entirely clear. Lung cancer carcinogenesis is a complex biological process involving a variety of genetic and epigenetic changes.[4](#tca12900-bib-0004){ref-type="ref"}, [5](#tca12900-bib-0005){ref-type="ref"}, [6](#tca12900-bib-0006){ref-type="ref"}, [7](#tca12900-bib-0007){ref-type="ref"}

Methylation of the CpG island is a common DNA modification and can change the activity of a DNA segment without changing the sequence. DNA methylation in the promoter region of certain genes typically acts to repress gene transcription.[8](#tca12900-bib-0008){ref-type="ref"}, [9](#tca12900-bib-0009){ref-type="ref"} DNA methylation has been proven essential for normal development and is associated with a number of key processes, including genomic imprinting, X‐chromosome inactivation, repression of transposable elements, aging, and carcinogenesis.[8](#tca12900-bib-0008){ref-type="ref"} DNA hypermethylation of CpG in the promoter regions causes inactivation of the tumor‐suppressor genes, which are involved in mechanisms such as apoptosis and the cell cycle.[9](#tca12900-bib-0009){ref-type="ref"}

*Epithelial cadherin* (E‐cadherin), also known as the *cadherin‐1* (*CDH1*) gene is a classic tumor suppressor gene.[10](#tca12900-bib-0010){ref-type="ref"}, [11](#tca12900-bib-0011){ref-type="ref"} Studies have indicated that loss of *E‐cadherin* function or expression is implicated in cancer progression and metastasis.[12](#tca12900-bib-0012){ref-type="ref"} One of the key mechanisms for loss of *E‐cadherin* expression is hypermethylation of the promoter region. Several studies have shown that the promoter region of the *E‐cadherin* gene is hypermethylated and is associated with a loss of expression.[13](#tca12900-bib-0013){ref-type="ref"}, [14](#tca12900-bib-0014){ref-type="ref"}, [15](#tca12900-bib-0015){ref-type="ref"} In the present study, we included all of the open published studies relevant to *E‐cadherin* promoter hypermethylation and non‐small cell lung cancer (NSCLC) to examine any correlation.

Methods {#tca12900-sec-0006}
=======

Database search {#tca12900-sec-0007}
---------------

The electronic PubMed, Embase, Web of Science, Google scholar, China National Knowledge Infrastructure, and Wanfang databases were systematic searched by two reviewers. Studies relevant to *E‐cadherin* gene promoter methylation and NSCLC were identified using the following keywords: "lung cancer," "carcinoma of the lung," "non‐small cell lung cancer," "NSCLC," "methylation," "hypermethylation," "E‐cadherin," "epithelial cadherin," "Cadherin‐1" and "CDH1." The title and abstract of the identified publications were reviewed to exclude unrelated studies. The full text of all potentially relevant publications was then reviewed to identify the suitable publications and extract the data.

Publication inclusion and data extraction {#tca12900-sec-0008}
-----------------------------------------

The inclusion criteria were: pathologically or cytologically confirmed NSCLC; and promoter hypermethylation of the *E‐cadherin* gene was detected via methylation‐specific PCR (MSP), real‐time MSP (RT‐MSP), quantitative MSP (q‐MSP), and MethyLight. Non‐malignant lung tissue or blood from the same patient was used as control material. All included studies were published in English or Chinese. General information, such as first author, study publication year, mean age of subjects included in each individual study, ethnicity, and hypermethylation detection methods, were extracted from each individual study. The hypermethylation status of the cancer tissue (CT) and autologous control (AC) were extracted by two reviewers and checked by a third reviewer, as recommended by the Cochrane Handbook for systematic reviews.[16](#tca12900-bib-0016){ref-type="ref"}

Statistical method {#tca12900-sec-0009}
------------------

Hypermethylation frequency in CT and AC was calculated as the hypermethylation rate. *E‐cadherin* gene promoter hypermethylation in CT compared to AC was expressed by odds ratio (OR) and 95% confidence intervals (CIs). Before pooling the data, statistical heterogeneity across the 11 included publications was assessed by I^2^ test. Fixed or random effect methods were used to pool the ORs, according to the I^2^ test. Correlation of hypermethylation status between CT and AC of NSCLC patients was evaluated by line regression test. Funnel plot and Egger\'s line regression test[17](#tca12900-bib-0017){ref-type="ref"} were used to assess publication bias. All data analysis was performed using STATA/SE 11.0 (StataCorp LP, <http://www.stata.com>).

Results {#tca12900-sec-0010}
=======

General information of the included publications {#tca12900-sec-0011}
------------------------------------------------

Seventy‐six relevant studies were initially identified. After reviewing the title and abstract, 53 publications were excluded for the following reasons: (i) subjects of the original studies had other malignant carcinomas; (ii) hypermethylation was detected in genes other than *E‐cadherin*; (iii) duplicated publications or data; (iv) control samples were from healthy subjects; and (v) studies were about cell lines. The full text of 32 studies was reviewed. Twelve publications were excluded as they did not include sufficient data to calculate the hypermethylation frequency of CT or AC. Eleven studies were finally included in the meta‐analysis (Fig [1](#tca12900-fig-0001){ref-type="fig"}).[13](#tca12900-bib-0013){ref-type="ref"}, [14](#tca12900-bib-0014){ref-type="ref"}, [15](#tca12900-bib-0015){ref-type="ref"}, [18](#tca12900-bib-0018){ref-type="ref"}, [19](#tca12900-bib-0019){ref-type="ref"}, [20](#tca12900-bib-0020){ref-type="ref"}, [21](#tca12900-bib-0021){ref-type="ref"}, [22](#tca12900-bib-0022){ref-type="ref"}, [23](#tca12900-bib-0023){ref-type="ref"}, [24](#tca12900-bib-0024){ref-type="ref"}, [25](#tca12900-bib-0025){ref-type="ref"} The general characteristics of the included 11 studies are shown in Table [1](#tca12900-tbl-0001){ref-type="table"}.

![PRISMA flowchart of database search.](TCA-10-54-g001){#tca12900-fig-0001}

###### 

General characteristics of the included publications

  Author                          Year publication   Location    Age (years)   Gender (M/F)   Ethnic         CT   AC   Method   Control type              
  ------------------------------- ------------------ ----------- ------------- -------------- ------------ ---- ---- -------- -------------- ------------ -------
  Zochbauer‐Muller *et al*.^18^   2001               Australia   NA            76/31          Caucasian      19   88        0            104 MSP          NMLT
  Yanagawa *et al*.^14^           2003               Japan       67.3 (mean)   54/21          East Asian     22   53       11             64 MSP          NMLT
  Russo *et al*.^15^              2005               US          NA            NA             Caucasian      18   31       11             38 MSP          Blood
  Kim *et al*.^12^                2007               Korea       NA            90/28          East Asian     30   58        5             83 MSP          NMLT
  Wang *et al*.^23^               2007               China       57 (median)   14/8           East Asian      9   13        2             20 MSP          NMLT
  Gu *et al*.^24^                 2007               China       NA            23/18                          8   33        0             41 MSP          NMLT
  Feng *et al*.^13^               2008               US          64.3 (mean)   26/23          Caucasian      15   34        4             45 MethyLight   NMLT
  Wang G *et al*.^20^             2008               China       58 (median)   19/76          East Asian     63   32       23             72 MSP          NMLT
  Wang Y *et al*.^21^             2008               China       NA            NA             East Asian      3   25        1             11 MSP          NMLT
  Liu *et al*.^22^                2009               US          NA            27/8           Mixed          10   25        4              6 MSP          NMLT
  Zheng *et al*.^25^              2012               China       NA            26/11          East Asian     12   25        0             25 MSP          NMLT

AC, autologous control; CT, cancer tissue; F, female; M, male; MSP, methylation‐specific PCR; NA, not available; NMLT, non‐malignant lung tissue.

Hypermethylation frequency in cancer tissue (CT) and autologous controls (AC) {#tca12900-sec-0012}
-----------------------------------------------------------------------------

The frequency of *E‐cadherin* gene promoter hypermethylation ranged from 0.11 to 0.66 in the CT and 0 to 0.40 in the AC of the included publications. The mean *E‐cadherin* gene promoter hypermethylation frequencies were 0.32 (95% CI 0.22--0.41) and 0.12 (95% CI 0.04--0.20) for CT and AC, respectively, with statistical difference (*P* \< 0.05) (Fig [2](#tca12900-fig-0002){ref-type="fig"}).

![Scatter plot of *E‐cadherin* gene promoter hypermethylation frequency in cancer tissue and autologous controls of non‐small cell lung cancer patients.](TCA-10-54-g002){#tca12900-fig-0002}

Meta‐analysis {#tca12900-sec-0013}
-------------

Statistical heterogeneity was evaluated by I^2^ test. Significant statistical heterogeneity was found across the included 11 publications (I^2^ = 54.5, *P* \< 0.05). The data was pooled through random effect model with an OR of 4.21 (95% CI 2.33--7.58) in CT compared to AC (Fig [3](#tca12900-fig-0003){ref-type="fig"}).

![Forest plot of *E‐cadherin* promoter hypermethylation in cancer tissue (CT) versus autologous controls (AC). The squares and horizontal lines represent the study‐specific odds ratio (OR) and 95% confidence interval (CI). The area of the squares reflects the weight (inverse of the variance). The diamond represents the pooled OR and 95% CI through random effect method.](TCA-10-54-g003){#tca12900-fig-0003}

Correlation of *E‐cadherin* gene promoter methylation between CT and AC {#tca12900-sec-0014}
-----------------------------------------------------------------------

Correlation of *E‐cadherin* gene promoter hypermethylation between CT and AC was evaluated by line regression test. Hypermethylation correlation between CT and AC can be demonstrated by Y = 0.3431\*X + 0.01231 (Fig [4](#tca12900-fig-0004){ref-type="fig"}).

![Scatter plot of the correlation of *E‐cadherin* gene promoter methylation between cancer tissue (CT) and autologous controls (AC).](TCA-10-54-g004){#tca12900-fig-0004}

Publication bias {#tca12900-sec-0015}
----------------

A Begg\'s funnel plot and Egger\'s line regression test were used to investigate possible publication bias. Slight asymmetry in the bottom of the funnel plot indicated potential publication bias; however, no publication bias was identified by Egger\'s line regression test (t = 0.58, *P* \> 0.05) (Fig [5](#tca12900-fig-0005){ref-type="fig"}).

![Funnel plot with pseudo 95% confidence limits (each circle represents a separate publication for the indicated association). The area of the hollow circle reflects the weight (inverse of the variance). SE, standard error.](TCA-10-54-g005){#tca12900-fig-0005}

Discussion {#tca12900-sec-0016}
==========

Tumor suppressor gene promoter methylation is considered an important mechanism to inactivate lung cancer progression.[1](#tca12900-bib-0001){ref-type="ref"}, [2](#tca12900-bib-0002){ref-type="ref"} *E‐cadherin* is a classic member of the cadherin superfamily. *E‐cadherin* mutation or loss of expression is correlated with the progression of several carcinomas, including lung, gastric, breast, colorectal, thyroid, and ovarian cancers. Loss of function is thought to contribute to progression in cancer by increasing proliferation, invasion, and/or metastasis. Promoter hypermethylation is an important mechanism that inactivates the *E‐cadherin* gene.[13](#tca12900-bib-0013){ref-type="ref"}, [19](#tca12900-bib-0019){ref-type="ref"}, [20](#tca12900-bib-0020){ref-type="ref"} Several studies have investigated the hypermethylation status in CT and AC of NSCLC patients; however, the hypermethylation frequency differs between studies.[22](#tca12900-bib-0022){ref-type="ref"}, [25](#tca12900-bib-0025){ref-type="ref"} In addition, the statistical power of each individual study was limited by small sample sizes. Therefore, the correlation between hypermethylation of the CpG island in the promoter region of the *E‐cadherin* gene and lung cancer risk is inconclusive.

In the present work, we investigated the correlation between *E‐cadherin* gene promoter hypermethylation and lung cancer risk by meta‐analysis. Eleven relevant publications were included and analysis showed that the frequency of *E‐cadherin* promoter hypermethylation in CT is significantly higher than in AC, indicating that promoter hypermethylation of *E‐cadherin* plays an important role in NSCLC carcinogenesis. Hypermethylation of the *E‐cadherin* the gene may increase the risk of lung cancer at an epidemiological level. However, the molecular mechanisms are yet to be elucidated.

In conclusion, *E‐cadherin* promoter hypermethylation is common in the CT of NSCLC patients and may play an important role in progression. However, the molecular mechanisms relevant to *E‐cadherin* promoter hypermethylation and lung cancer progression are not yet clear. Therefore, studies of the molecular mechanisms of *E‐cadherin* promoter hypermethylation and lung cancer are needed.
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